Indian drugmaker Biocon (BSE: 532523) has entered a five-year partnership with Sandoz (SIX: SDZ), which provides the Swiss firm with exclusive rights to promote, sell and distribute biosimilar trastuzumab (market value of A$35 million [US$53.5 million]) and biosimilar bevacizumab (market value of A$45 million) in Australia.
Trastuzumab is a biosimilar of Roche’s (ROG: SIX) Herceptin, with bevacizumab referencing the Swiss pharma giant cancer drug Avastin.
Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, Ogivri (bTrastuzumab) and Abevmy (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze